重组人白细胞介素11治疗急性白血病化疗所致血小板减少的多中心研究  

Recombinant human interleukin.ll for chemotherapy-induced thrombocytopenia of acute leukemia：a multi-center study

作　　者：崔新宇 周虹[2] 李英花[3] 郑立[4] 白莲 刘娜[2] 曲延章[2] 姜丽波[2] 陈三军[6] Cui Xinyu;Zhou Hong;Li Yinghua;Zheng Li;Bai Lian;Liu Na;Qu Yanzhang;Jiang Libo;Chert Sanjun(Department of Hematology, the Third Affiliated Hospital of Qiqihar Medical University, Qiqihar 161000, China （Cui XY;Department of Hematology, the Second Affiliated Hospital of Qiqihar Medical University, Qiqihar 161006, China （Zhou H, Liu N, Qu YZ, Jiang LB;Department of Hematology, the First Affiliated Hospital of Harbin Medical University, Harbin 150001, China （Li YH;Department of Hematology, the Guangyuan Central Hospital, Guangyuan 628000, China （Zheng L;Department of Hematology, Canglang Hospital of Suzhou, Suzhou 215000, China （Bai L;Department of Hematalogy, the Second Affiliated Hospital of Nanchang University, Nanchang 330000, China （Chert S J)

机构地区：[1]齐齐哈尔医学院附属第三医院血液科,161000 [2]齐齐哈尔医学院附属第二医院血液科,161006 [3]哈尔滨医科大学附属第一医院血液科,150001 [4]四川省广元市中心医院血液科,628000 [5]苏州沧浪医院血液科,215000 [6]南昌大学第二附属医院血液科,330000

出　　处：《白血病．淋巴瘤》2018年第5期276-279,共4页Journal of Leukemia & Lymphoma

摘　　要：目的探究重组人白细胞介素11（rhIL-11）治疗急性白血病化疗所致血小板减少症的效果及安全性。方法纳入2016年2月至7月全国6个中心急性白血病化疗后血小板减少症[血小板计数（Plt）〈50×109/L]患者，给予rhIL-11皮下注射治疗，2 mg/次，2次/d，连续使用7 d或至Plt经最低值后恢复到≥50×109/L时停用，观察受试者Plt恢复情况。结果共入组患者112例，2例退出。110例有效病例中，rhIL-11治疗的总有效率为74.5%（82/110），治疗前后受试者Plt回升平均量为（70±54）×109/L，治疗有效者Plt恢复的平均时间为（8.7±3.0）d。在重度血小板减少症的治疗上，单药rhIL-11治疗与rhIL-11联合血小板输注治疗相比，受试者Plt恢复时间缩短，差异有统计学意义[（8.0±2.6）d比（9.6±3.5）d，t=2.17，P=0.03]。结论rhIL-11 2次/d皮下注射的给药方式可加速血小板恢复，降低血小板输注率，不良反应少，值得临床推广应用。To explore the efficacy and safety of recombinant human interleukin-11 （rhIL-11） in treatment of chemotherapy-induced thrombocytopenia of acute leukemia.MethodsAcute leukemia patients with chemotherapy-induced thrombocytopenia [Platelets （Plt） 〈 50×109/L] in 6 centers nationwide from February 2016 to July 2016 were treated with rhIL-11 （2 mg/time, twice per day） by subcutaneous injection. Treatment lasted 7 days or at least until Plt≥ 50×109/L. The Plt recovery was observed during treatment.ResultsA total of 112 patients were enrolled, and 2 patients decided to drop out of study. The efficacy population consisted of 110 patients, and the total response rate reached 74.5% （82/110）. The average variation of Plt during treatment was （70±54）×109/L, and recovery average time of Plt for the patients with favorable efficacy was （8.7±3.0） days. In treatment with severe thrombocytopenia, rhIL-11 alone could shorten the recovery time compared with rhIL-11 combined with Plt transfusion [（8.0±2.6） d vs. （9.6±3.5） d, t=2.17, P=0.03].ConclusionrhIL-11 twice a day of subcutaneous injection can effectively promote Plt recovery and reduce Plt transfusion with less adverse reactions, which is worthy of further application.

关 键 词：白血病 急性 血小板减少症 白细胞介素11 

分 类 号：R733.71[医药卫生—肿瘤]